{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Casciola M"],"pubmed_abstract":["<h4>Introduction</h4>Pulsed Field Ablation (PFA) is a novel non-thermal method for cardiac ablation, relying on irreversible electroporation induced by high-energy pulsed electric fields (PEFs) to create localized lesions in the heart atria. A significant challenge in optimizing PFA treatments is determining the lethal electric field threshold (EFT), which governs ablation volume and varies with PEF waveform parameters. However, the proprietary nature of device developer's waveform characteristics and the lack of standardized nonclinical testing methods have left optimal EFTs for cardiac ablation uncertain.<h4>Methods</h4>To address this gap, we introduced a laboratory protocol employing human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in monolayer format to evaluate "],"journal":["Frontiers in physiology"],"pagination":["1395923"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11190366"],"repository":["biostudies-literature"],"pubmed_title":["Pulsed electric field performance calculator tool based on an <i>in vitro</i> human cardiac model."],"pmcid":["PMC11190366"],"pubmed_authors":["Casciola M","Kaboudian A","Narkar A","Blinova K","Feaster TK"],"additional_accession":[]},"is_claimable":false,"name":"Pulsed electric field performance calculator tool based on an <i>in vitro</i> human cardiac model.","description":"<h4>Introduction</h4>Pulsed Field Ablation (PFA) is a novel non-thermal method for cardiac ablation, relying on irreversible electroporation induced by high-energy pulsed electric fields (PEFs) to create localized lesions in the heart atria. A significant challenge in optimizing PFA treatments is determining the lethal electric field threshold (EFT), which governs ablation volume and varies with PEF waveform parameters. However, the proprietary nature of device developer's waveform characteristics and the lack of standardized nonclinical testing methods have left optimal EFTs for cardiac ablation uncertain.<h4>Methods</h4>To address this gap, we introduced a laboratory protocol employing human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in monolayer format to evaluate ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-04T12:47:39.29Z","creation":"2025-04-04T12:47:39.29Z"},"accession":"S-EPMC11190366","cross_references":{"pubmed":["38911328"],"doi":["10.3389/fphys.2024.1395923"]}}